[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100633944":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":33,"centralContacts":42,"locations":48,"responsibleParty":62,"collaborators":33,"id":64,"slug":65,"hasResults":66,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":33,"eligibilityCriteria":70,"healthyVolunteers":66,"sex":71,"minAge":72,"maxAge":33,"enrollmentInfo":73,"targetDuration":33,"studyType":76,"phases":77,"briefSummary":79,"conditions":80,"keywords":33,"overallStatus":82,"whyStopped":33,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"Daewoong Pharmaceutical Co. LTD.","INDUSTRY",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Fexuprazan 20mg","EXPERIMENTAL","Fexuprazan 20mg orally, once daily",[13,14],"Drug: Fexuprazan 20mg","Drug: Lansoprazole 15 mg placebo",{"label":16,"type":17,"description":18,"interventionNames":19},"Lansoprazole 15mg","ACTIVE_COMPARATOR","Lansoprazole 15mg orally, once daily",[20,21],"Drug: Lansoprazole 15 mg","Drug: Fexuprazan 20mg placebo",[23,29,34,38],{"type":24,"name":9,"description":25,"armGroupLabels":26,"otherNames":27},"DRUG","Fexuprazan 20mg, tablet, orally, once daily for up to 24 weeks",[9],[28],"Fexuclue",{"type":24,"name":30,"description":31,"armGroupLabels":32,"otherNames":33},"Lansoprazole 15 mg placebo","Lansoprazole 15mg placebo matching capsule, orally, once daily for up to 24 weeks",[9],null,{"type":24,"name":35,"description":36,"armGroupLabels":37,"otherNames":33},"Lansoprazole 15 mg","Lansoprazole 15mg capsule, orally, once daily for up to 24 weeks",[16],{"type":24,"name":39,"description":40,"armGroupLabels":41,"otherNames":33},"Fexuprazan 20mg placebo","Fexuprazan 20mg placebo-matching tablet, orally, once daily for up to 24 weeks",[16],[43],{"name":44,"role":45,"phone":46,"phoneExt":33,"email":47},"Dr. Lee, MD, PhD","CONTACT","821025858941","2210498@daewoong.co.kr",[49],{"facility":50,"status":33,"city":51,"state":33,"zip":33,"country":52,"countryCode":33,"cosmosGeoPoint":53,"geoPoint":58,"contacts":59},"Asan Medical Center","Seoul","South Korea",{"type":54,"coordinates":55},"Point",[56,57],126.9784,37.566,{"lat":57,"lon":56},[60],{"name":61,"role":45,"phone":46,"phoneExt":33,"email":47},"Dr. Lee",{"type":63,"investigatorFullName":33,"investigatorTitle":33,"investigatorAffiliation":33,"oldNameTitle":33,"oldOrganization":33},"SPONSOR","100633944","phase-4-study-to-evaluate-the-efficacy-and-safety-of-fexuprazan-in-prevention-of-nsaids-induced-peptic-ulcer-100633944",false,"NCT07533266","Study to Evaluate the Efficacy and Safety of Fexuprazan in Prevention of NSAIDs Induced Peptic Ulcer","A Multi-center, Randomized, Double-blind, Parallel-group, Active-controlled, Phase IV Clinical Trial to Evaluate the Efficacy and Safety of Fexuclue Tab. in Prevention of NSAIDs-induced Peptic Ulcer","Inclusion Criteria:\n\n1. Male and female adults aged ≥ 19 years at the time of informed consent\n2. Subjects who are diagnosed with musculoskeletal disease at screening and require continued treatment with NSAIDs for at least 24 weeks\n3. Subjects with at least one of the following risk factors for ulcer development at screening.\n4. Subjects who have no gastric or duodenal mucosal break or have ulcer in the scarring stage based on the EGD result at screening.\n\nExclusion Criteria:\n\n1. Subjects with esophagitis, gastroesophageal varix, esophagus, Barrett's esophagus, acute gastrointestinal bleeding and else based on the screening EGD results.\n2. Subjects who have undergone gastroduodenal surgery or total small bowel resection\n3. Subjects with history of clinically significant disease of hepatic, renal, nervous, pulmonary, endocrine, hemato-oncologic, cardiovascular or urinary system\n4. Subjects who have had a malignant tumor in the last 5 years\n5. Subjects who history of hypersensitivity to the IP ingredients, aspirin and NSAIDs","ALL","19 Years",{"count":74,"type":75},360,"ESTIMATED","INTERVENTIONAL",[78],"PHASE4","The study aims to demonstrate the preventive effect of Fexuprazan 20 mg for peptic ulcer is non-inferior to that of Lansoprazole 15 mg in terms of prevention of peptic ulcer and confirm the safety of Fexuprazan 20 mg.",[81],"NSAID (Non-Steroidal Anti-Inflammatory Drug)","NOT_YET_RECRUITING","2026-04-14",{"date":85,"type":86},"2026-04-16","ACTUAL",{"date":88,"type":75},"2026-04",{"date":90,"type":75},"2027-12",{"name":5,"class":6},1]